VTAMA Demonstrates Early and Consistent Skin Clearance Across Pediatric and Adult Age Groups with Atopic Dermatitis – Organon

Organon will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the efficacy and safety of Vtama cream versus vehicle at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis, Minnesota.
Vtama cream is the first and only aryl hydrocarbon receptor (AhR) agonist indicated for the treatment of both atopic dermatitis in adults and pediatric patients 2 years and older and plaque psoriasis in adults.

The findings show that Vtama cream demonstrated early and consistent improvements in disease severity—as measured by vIGA-AD and EASI75—across three pediatric age groups and adults with moderate to severe atopic dermatitis.

“Patients can experience atopic dermatitis differently across all stages of life. In my practice I might treat a toddler differently than a teenager or adult. Having robust, age-stratified data gives us real confidence in how we counsel patients and families. This data is encouraging, as it shows whether patients were young children or adults, have moderate or severe atopic dermatitis, Vtama cream demonstrated clinically meaningful early and consistent improvements in skin clearance.” – Luz Fonacier, MD, Professor, Department of Medicine at NYC Grossman Long Island School of Medicine and Lead Author of the poster being presented at SPD.

In the ADORING 1 and ADORING 2 pivotal trials, adults and children 2 years and older (N=813) with moderate to severe atopic dermatitis were randomized 2:1 to Vtama cream or vehicle once daily for 8 weeks. The findings presented at SPD 2026 stem from a post hoc analysis of pooled data stratified by age group: 2–6 years, 7–11 years, 12–17 years, and 18 years and older.1 Most patients (80.4%) were aged 2–17 years, reflecting the higher prevalence of atopic dermatitis in pediatric populations.

Improvements with Vtama cream were observed as early as week 2, the first post-treatment assessment across pediatric age groups, and they continued through week 8.

Vtama cream demonstrated consistent improvements in skin clearance (vIGA-AD response) compared to vehicle at week 8 across pediatric age groups:

• 2–6 years: 56.3% vs. 11.8% (P<0.0001)
• 7–11 years: 44.9% vs. 23.8% (P=0.0172)
• 12–17 years: 48.8% vs. 13.4% (P<0.0001)
• ≥18 years: 38.0% vs. 18.1% (P=0.0280)

Vtama cream also showed consistent improvements in the proportion of patients achieving at least a 75% reduction in EASI75 at week 8:

• 2–6 years: 70.2% vs. 20.5% (P<0.0001)
• 7–11 years: 53.6% vs. 31.3% (P=0.0158)
• 12–17 years: 62.2% vs. 18.3% (P<0.0001)
• ≥18 years: 50.8% vs. 20.6% (P=0.0020)

The most common treatment-emergent adverse events in patients with atopic dermatitis were folliculitis, headache, and nasopharyngitis. These were generally mild or moderate in severity. Treatment discontinuations due to treatment-related adverse events occurred less frequently with Vtama cream than with vehicle.

“What stands out in these data is not just the skin clearance patients achieved by week 8, but that these results were seen consistently across pediatric age groups as early as week 2. Organon is committed to advancing dermatology care, and findings like these reinforce Vtama cream as a valuable nonsteroidal option for a wide range of patients.” – Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon.

First-in-class Vtama cream is the only steroid-free, topical AhR agonist approved by the US Food and Drug Administration (FDA) for the topical treatment of atopic dermatitis in adults and pediatric patients two years of age and older and the topical treatment of plaque psoriasis in adults. The American Academy of Dermatology (AAD) provided strong recommendations for use of Vtama cream for the treatment of pediatric and adult atopic dermatitis patients.